GlassScriptPhysician profile
Casey Burnette
NPI 1063906584
$2,506.76
in general payments reported to CMS, 2019-2025
21 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.47 · 2022: $375 · 2023: $851 · 2024: $795 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,988 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,987.78 |
| Education | $101.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.11 | 2022-2025 | |
| Janssen Biotech, INC. | $290.29 | 2023-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $134.65 | 2022-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $122.99 | 2021-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $91.71 | 2022-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.66 | 2023-2024 | Xifaxan, Trulance |
| Pfizer INC. | $72.66 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $70.99 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $47.98 | 2021-2023 | |
| Genzyme Corporation | $43.35 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $42.24 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $33.75 | 2023 | Ibsrela |
| Fresenius Kabi USA, LLC | $27.61 | 2024 | Idacio |
| Organon LLC | $25.86 | 2023 | Renflexis |
| Celgene Corporation | $24.24 | 2024 | Zeposia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $21.40 | 2024 | Hyrimoz |
| Aimmune Therapeutics, INC. | $17.40 | 2023 | |
| Lilly USA, LLC | $14.82 | 2024 | Omvoh |
| Ferring Pharmaceuticals INC. | $14.21 | 2025 | Rebyota |
| Glaxosmithkline, LLC. | $13.98 | 2024 | Shingrix, Arexvy |
| Ipsen Biopharmaceuticals, INC | $13.86 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Burnette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.